青光眼视野进展复发率及危险因素
该队列研究纳入5086例开角型青光眼或疑似青光眼患者的7457只眼,评估首次GPA可能进展事件后复发性视野进展的发生率及相关因素。首次进展后635只眼有充分随访,其中26.3%复发,3年累积复发率13.8%、10年43.5%。首次进展前MD下降更快、事件后平均眼压更高、首次进展时MD损伤较轻及年龄更大与复发独立相关。
要点
- 首次GPA进展后复发常见,10年累积复发率达43.5%。
- 事件前MD下降快、事件后眼压高、年龄大者复发风险更高。
- 眼压每多降10%,复发风险降低(HR 0.89)。
核心结论
- 首次GPA可能进展事件后复发性视野进展常见,高风险眼具有事件前视野丢失更快、首次进展时损伤较轻、事件后眼压更高及年龄更大的特征。
研究设计与样本
- 1998至2025年在单一三级学术中心(Bascom Palmer眼科登记库)开展的队列研究,纳入5086例开角型青光眼或疑似青光眼患者的7457只眼。
- 平均(SD)随访12.4(4.6)年,患者平均(SD)年龄60.5(13.1)岁,4468只眼(59.9%)来自女性患者。
主要发现
- 1951只眼(26.2%)发生首次GPA可能进展,其中635只眼在首次进展后有充分随访和眼压数据。
- 635只眼中167只眼(26.3%)复发,Kaplan-Meier累积复发率3年为13.8%(95%CI 11.6%-17.1%)、10年为43.5%(95%CI 35.8%-52.1%)。
- 多变量Cox分析中,首次进展前MD下降更快(每1 dB/y,HR 1.73;95%CI 1.39-2.15)、事件后平均眼压更高(每1 mmHg,HR 1.09;95%CI 1.05-1.13)、首次进展时MD较不负面(每1 dB,HR 1.08;95%CI 1.04-1.12)及年龄更大(每5岁,HR 1.11;95%CI 1.03-1.19)与复发独立相关。
- 眼压每多降低10%与更低的复发风险相关(HR 0.89;95%CI 0.83-0.94)。
- 事件前MD斜率快于-1.0 dB/y的眼复发率为42.7%,慢于该值的眼为23.4%(差异19.3%;95%CI 8.8%-29.9%)。
关键数值与推荐
- 首次GPA可能进展后复发定义基于GPA事件,复发累积概率采用Kaplan-Meier法估计。
- 事件前MD斜率快于-1.0 dB/y的眼复发率42.7%,慢于-1.0 dB/y的眼复发率23.4%(差异19.3%;95%CI 8.8%-29.9%)。
临床怎么用
- 对首次GPA进展后事件前视野丢失快、事件后眼压高、年龄大或首次进展时损伤较轻的眼,可考虑加强监测和降眼压治疗。
局限性
- 研究为单一三级学术中心队列,首次进展后仅635只眼有充分随访和眼压数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A confirmed visual field progression event in glaucoma typically prompts intensification of intraocular pressure (IOP)-lowering therapy, yet the factors associated with recurrent progression after that first event remain poorly characterized. OBJECTIVE: To evaluate the incidence of recurrent visual field progression after an initial Guided Progression Analysis (GPA) likely-progression event and the factors associated with a recurrent event. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted among patients receiving routine ophthalmic care between 1998 and 2025 at a single tertiary academic center (Bascom Palmer Ophthalmic Registry). Data were analyzed from February 2026 to August 2026. MAIN OUTCOMES AND MEASURES: The primary outcomes were the cumulative probability of recurrent visual field progression and hazard ratios (HRs) for factors associated with recurrence. RESULTS: A total of 7457 eyes of 5086 patients with open-angle glaucoma or suspected glaucoma were included, with a mean (SD) follow-up of 12.4 (4.6) years. Mean (SD) patient age was 60.5 (13.1) years, and 4468 eyes (59.9%) were from female patients. By self-reported race and ethnicity, 203 eyes (2.7%) were from Asian patients, 1718 (23.0%) from Black patients, 1677 (22.5%) from Hispanic patients, and 5536 (74.2%) from White patients. A total of 1951 eyes (26.2%) developed initial GPA likely progression; 635 eyes had adequate follow-up after first progression and IOP data. Among those, 167 (26.3%) recurred. Kaplan-Meier cumulative recurrence was 13.8% at 3 years (95% CI, 11.6%-17.1%) and 43.5% at 10 years (95% CI, 35.8%-52.1%). In multivariable Cox analysis, faster mean deviation (MD) loss before first progression (HR, 1.73 per 1 decibel [dB]/y; 95% CI, 1.39-2.15), higher mean IOP after the first event (HR, 1.09 per 1 mm Hg; 95% CI, 1.05-1.13), less negative MD at first progression (HR, 1.08 per 1 dB; 95% CI, 1.04-1.12), and older age (HR, 1.11 per 5 years; 95% CI, 1.03-1.19) were independently associated with recurrence. Each 10% greater IOP reduction was associated with lower hazard (HR, 0.89; 95% CI, 0.83-0.94). Among eyes with pre-event MD slopes faster than -1.0 dB/y, recurrence occurred in 42.7% of eyes vs 23.4% in slower-progressing eyes (difference, 19.3%; 95% CI, 8.8%-29.9%). CONCLUSIONS AND RELEVANCE: Findings from this cohort study suggest that recurrent visual field progression after a first GPA progression event is common; eyes at highest risk had faster pre-event visual field loss, less advanced damage at first progression, higher postevent IOP, and older age. These results may help target intensified monitoring and IOP lowering toward higher-risk eyes.
引用
- Malek DA, da Costa DR, Scherer R, et al. Incidence and Risk Factors of Recurrent Visual Field Progression in Glaucoma. JAMA Ophthalmol. 2026. PMID: 42911573. doi:10.1001/jamaophthalmol.2026.4609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。